India has approved Novo Nordisk's obesity drug Wegovy for the treatment of fatty liver disease. This marks an expansion of the drug's approval beyond weight management. The decision could impact millions in India with non-alcoholic fatty liver disease. The approval follows similar moves in other countries.
No infographic was generated for this story. GreyNews is not leaving this spinning indefinitely.
Partial · Low confidence (25%)
Same as the summary above — this brief adds the distinct fields below.
No impact angle yet.
0 verified / 0 claims
No flagged uncertainty yet.
No forecast extracted yet.
India approves Novo Nordisk's…
Emotionally neutral rewrite. Same facts, calmer framing.